SPARTANBURG COMMUNITY CLINICAL ONCOLOGY PROGRAM

在作为CCOP 12年经验的基础上，斯帕坦堡社区 临床肿瘤学计划(SCCOP)寻求继续 满足我们的社区对创新和相关研究的需求 2001年的治疗方式和癌症控制研究。 SCCOP提供了国家合作临床试验的途径 近50万人口分布在6个县：3个在南卡罗来纳州，3个在美国 北卡罗来纳州。南卡罗来纳州的人口密度和排名都排在第21位 在医疗服务不足的百分比中排名第14。服务区有 20%的少数族裔基数。地区登记处报告了1100多种新的癌症 自1982年以来，每年增加超过158%的患者。反对这一点 在农村背景下，我们制定了一个三院联合体的行为 社区临床试验。独特的能力体现在 少数人应计超过17%，以及#年服务不足的84个条目的应计 过去的七年里。 SCCOP汇聚了一组 合作进行研究的多学科调查人员 来自SWOG、NSABP、RTOG和MDACC。46名调查人员包括一名单一的， 小规模、稳定、高效的3项实践 血液学家/肿瘤学家和41位病理学、放射学方面的同事 治疗、外科、耳鼻咽喉科、泌尿科、胃肠病学以及内科 医药。自20世纪90年代初以来，该集团的规模几乎增加了两倍，S和 自1983年以来，总共为临床试验贡献了1700多个条目， CCOP的开始。 未来五年，总体目标是降低癌症发病率， 发病率和死亡率通过加速转移新开发的 癌症预防、早期发现、治疗、病人管理、 康复和持续护理技术推广到广泛的社区 申请。经过精心设计，该计划将集中我们60%以上的 癌症控制研究方面的资源。这些互补的目标 治疗和癌症控制对患者来说都是现成的匹配 符合SCCOP的兴趣和能力。 SCCOP的近期目标是将我们的应计比率提高到 治疗试验；保持社区的广泛参与，包括 在治疗和癌症方面，少数群体和服务不足的人群 NCI批准的对照研究；并继续完善癌症控制 数据管理能力，包括使用一系列资源来 确定癌症控制研究项目的潜在候选者。这个 继续乳腺癌预防试验(BCPT)，前列腺癌 癌症预防试验(PCPT)、结直肠预防试验和 即将到来的吸烟者化学预防试验是主要目标。 总而言之，SCCOP的跟踪记录证明了管理能力 生产过程中复杂的临床研究和癌症控制活动 最高质量的数据。SCCOP设施齐全，训练有素 专业人员配套齐全的学习。SCCOP 人员配置模式、礼仪管理程序、患者/参与者 管理方法、质量控制机制、国税局结构和 所有联络员都已就位，并发挥着支持当前和未来的作用 治疗和癌症控制活动。 在未来五年，我们预计将为 国家癌症研究所社区临床肿瘤学项目：超过133个 每年治疗学分和超过183个癌症控制学分 2001年。

Building on 12 years of experience as a CCOP, the Spartanburg Community Clinical Oncology Program (SCCOP) seeks the opportunity to continue to meet our community's need for innovative and relevant studies of promising therapeutic modalities and cancer control research through the Year 2001. The SCCOP provides access to national cooperative clinical trials to nearly a half million people in 6 counties: 3 in South Carolina and 3 in North Carolina. South Carolina is 21st in population density and ranks 14th in the percent who are medically underserved. The service area has a 20% minority base. The regional registry reports over 1,100 new cancer patients per year, an increase of over 158% since 1982. Against this rural background, we developed a three hospital consortium for the conduct of community clinical trials. Unique capacities are demonstrated by the minority accrual over 17% and by the underserved accrual of 84 entries in the last seven years. The SCCOP brings together the strength and resources of a group of multidisciplinary investigators who collaborate in the conduct of studies from SWOG, NSABP, RTOG, and MDACC. The 46 investigators include a single, small, stable, and highly productive practice of 3 hematologists/oncologists along with 41 colleagues in pathology, radiation therapy, surgery, ENT, urology, gastroenterology, as well as internal medicine. The group nearly tripled in size since the early 1990's and together has contributed over 1700 entries to clinical trials since 1983, the start of the CCOP. Over the next five years, the overall aim is to reduce cancer incidence, morbidity, and mortality by accelerating the transfer of newly developed cancer prevention, early detection, treatment, patient management, rehabilitation, and continuing care technology to widespread community application. By careful design, the program will focus over 60% of our resources on cancer control research. These complementary objectives of both treatment and cancer control are a ready match for the patient population and fit within SCCOP interests and capabilities. The immediate goals of the SCCOP are to increase our accrual rate to treatment trials; to maintain wide community participation, including minority groups and underserved populations, in both treatment and cancer control research approved by NCI; and to continue to refine cancer control data management capabilities, including the use of a range of resources to identify potential candidates for cancer control research projects. The continuation of the Breast Cancer Prevention Trial (BCPT), the Prostate Cancer Prevention Trial (PCPT), the Colorectal Prevention Trials, and the upcoming Smoker's Chemoprevention Trial are primary objectives. In summary, the SCCOP track record demonstrates the ability to manage complex clinical research and cancer control activities while producing the highest quality data. The SCCOP has the facilities and well-trained professional personnel to support the full array of studies. The SCCOP staffing pattern, protocol management procedures, patient/participant management approaches, quality control mechanisms, IRS structure and liaison are all in place and functioning to support current and future therapeutic and cancer control activities. Over the next five years, we expect to contribute over 1500 credits to the National Cancer Institute's Community Clinical Oncology Program: over 133 treatment credits and over 183 cancer control credits each year through 2001.